STRATENITY · INDUSTRY ONE-PAGER · PHARMACEUTICAL
CONFIDENTIAL · JULY 2026
Pharmaceutical
Industry Outlook · US Market · 2026
Scan Type
Industry Snapshot
Structured, repeatable read of sector economics, signals, gaps, and engagement pathways.
US Market
~$630B rx spend
~$200B+ branded revenue facing patent cliff
Net drug spend growth ~5-8% / yr
STRATENITY READ · Pharmaceutical is a high-stakes, capital-intensive sector where a single approved asset can carry a company and a single trial failure can erase a decade of investment. The core tension is durable: bringing a drug to market now costs roughly $2 to $2.8 billion capitalized over 10 to 15 years, while only about one in ten candidates that enter Phase 1 ever reaches approval. Two forces now compress the back end of that economics: a patent cliff exposing more than $200B of branded revenue this decade, and IRA Medicare price negotiation that shortens the effective monopoly window for small molecules and biologics. Organizations that win will impose portfolio go/no-go discipline, validate AI-driven discovery against real biology, de-risk trials through better recruitment and enrichment, and design launch and lifecycle strategy around IRA timelines and payer evidence. The advantage goes to operators who treat discovery, development, and market access as one governed, evidence-backed operating problem rather than isolated functional silos.
$2-2.8B
Cost per Approval
Capitalized R&D cost to bring one new drug to market.
10-15yr
Development Time
Discovery to approval; long, front-loaded capital exposure.
~10-12%
Ph1-to-Approval
Clinical success rate; attrition concentrated in Phase 2.
$200B+
Patent Cliff Exposure
Branded revenue losing exclusivity this decade.
9 / 13yr
IRA Eligibility Window
Years post-approval for small molecules / biologics.
~$630B
US Rx Spend
Total US prescription drug expenditure, list-price basis.
01 Industry Profile
Sub-sectorsBranded Rx, Biologics, Generics/Biosimilars, CRO/CDMO
Market size~$630B US Rx spend (2026)
R&D economics~$2-2.8B and 10-15 yrs per approval
Clinical success~10-12% Phase 1 to approval
RegulatorsFDA / EMA; GxP and 21 CFR Part 11
02 Cycle Drivers
1
Patent cliff. Over $200B of branded revenue loses exclusivity this decade, forcing pipeline replacement and M&A.
2
IRA price negotiation. Medicare negotiation from 9 years (small molecules) and 13 years (biologics) reshapes launch and lifecycle value.
3
AI in discovery. Protein-structure prediction and generative chemistry compress early discovery, but demand real-world validation.
4
Payer evidence and access. Real-world evidence and HEOR now gate formulary access and negotiated pricing as much as the label.
Major Players
Pfizer
Johnson & Johnson
Merck
AbbVie
Eli Lilly
Novartis
Roche
03 Industry Signals
Patent cliff and IRA pricing
More than $200B of branded revenue faces loss of exclusivity while IRA negotiation shortens the effective monopoly window, squeezing lifetime asset value.
AI in discovery and protein structure
Generative chemistry and structure prediction accelerate target and lead identification, but wet-lab and clinical validation remain the binding constraint.
Trial design and patient enrichment
Biomarker-driven enrichment and adaptive designs cut cost and time, yet recruitment and site execution still gate program timelines.
Real-world evidence for payer access
RWE and HEOR increasingly determine formulary placement and negotiated price, moving evidence generation upstream in the lifecycle.
Open innovation and biotech in-licensing
Pipeline gaps drive in-licensing, partnerships, and acquisition of biotech assets, raising the premium on partner and diligence discipline.
05 Sector Recommendations
NowImpose portfolio stage-gate discipline that scores every asset on probability of success, IRA-adjusted lifetime value, and capital at risk.
30-60dStand up an AI-discovery validation layer that ties in-silico predictions to wet-lab and translational evidence before spend escalates.
60-90dBuild an IRA-aware launch and lifecycle model integrating RWE, payer access, and indication sequencing across the negotiation window.
04 Industry Gap Analysis
G1
Portfolio go/no-go discipline. Sunk-cost bias and weak stage-gates keep marginal assets alive, diluting capital away from winners.
G2
AI-discovery validation. In-silico hits outrun experimental validation; predictions lack governed links to real biology and translational data.
G3
Trial recruitment and enrichment. Slow accrual and poor patient enrichment inflate timelines and cost, and undermine statistical power.
G4
IRA lifecycle strategy. Launch and indication sequencing rarely account for the 9 and 13 year negotiation clocks and eroding lifetime value.
G5
RWE and payer access. Evidence generation lags launch; HEOR and RWE arrive too late to shape formulary and negotiated price.
G6
CRO and partner governance. In-licensing and outsourced trials outpace diligence, quality oversight, and GxP-aligned partner controls.
Stratenity Signal Profile
Regulatory
FDA / EMA / IRA
Primary Domain
Portfolio & Development Economics
Recommended Module
VelorStrategy · Execution Workspace
Suggested assets: Portfolio Stage-Gate Model · IRA Lifecycle Playbook · RWE & Access Kit
Data confidence: High (public sources)
Last reviewed: July 2026
06 Strategic Engagement Opportunities
| Engagement Track | Strategic Thesis | $ Range |
|---|
| Portfolio Stage-Gates | Score every asset on probability of success, IRA-adjusted lifetime value, and capital at risk to concentrate spend on winners. | $300K-$2M |
| AI Discovery Validation | Tie in-silico target and lead predictions to governed wet-lab and translational evidence before escalating spend. | $250K-$1.5M |
| Trial Design + Optimization | Deploy biomarker enrichment, adaptive designs, and recruitment analytics to cut trial cost and timeline. | $220K-$1.4M |
| IRA Launch Sequencing | Model launch and indication sequencing around the 9 and 13 year negotiation clocks to protect lifetime value. | $200K-$1.2M |
| RWE / HEOR + Access | Build real-world evidence and health economics to shape formulary placement and negotiated pricing upstream. | $180K-$1M |
| Partner / CRO Governance | Stand up diligence, quality oversight, and GxP-aligned controls across in-licensing and outsourced trials. | $150K-$900K |
| Commercial Model Redesign | Re-engineer the commercial and market-access operating model for an IRA-constrained pricing environment. | $180K-$1.1M |
Total Addressable Engagement Value
$1.5M - $9.1M
across a 12-24 month engagement horizon
·Industry Outlook
Repeatable, versioned sector read covering economics, signals, gaps, and cycle drivers.
·Competitor Scans
Structured profiles of pharma, biotech, and CRO/CDMO players with pipeline and positioning.
·Market Entry Scan
Entry, in-licensing, and partnership analysis scoped to a target therapeutic area or asset.
·Bespoke / Regulatory
Advisory on FDA/EMA, GxP and 21 CFR Part 11, and IRA exposure plus governed AI deployment paths.
We can build this same industry view on any sector your clients pursue.
One repeatable, governed format across every market you advise, from pharmaceutical to fintech to energy.
REQUEST A SECTOR SCAN